|
|
- Cemiplimab - Wikipedia
In November 2022, the FDA approved cemiplimab in combination with platinum-based chemotherapy for adults with advanced non-small cell lung cancer with no EGFR, ALK, or ROS1 aberrations
- Cemiplimab Uses, Side Effects Warnings - Drugs. com
What is cemiplimab? Cemiplimab is used to treat certain cancers of the skin Cemiplimab is also used alone or in combination with other cancer drugs to treat lung cancer that has not spread outside your chest
- LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC
- Cemiplimab-rwlc - NCI - National Cancer Institute
Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy) It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells
- FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous . . .
On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
- Cemiplimab-rwlc (intravenous route) - Side effects uses
Cemiplimab-rwlc injection is used to treat a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread (metastatic) or cannot be cured by surgery or radiation (locally advanced)
- Cemiplimab (Libtayo®) - ChemoExperts
Cemiplimab is given to decrease symptoms from non-small-cell lung cancer (NSCLC) and to slow its spread to other parts of the body Cemiplimab is not commonly given with the goal of cure
- Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell . . .
Patients were assigned in a 1:1 ratio to receive adjuvant cemiplimab (350 mg) or placebo, administered intravenously every 3 weeks for 12 weeks, followed by a dose increase to 700 mg administered
- Libtayo (cemiplimab) dosing, indications, interactions, adverse effects . . .
Monoclonal antibody that targets checkpoint inhibitor PD-1 (programmed death 1) and blocks its interaction with PD-L1 and PD-L2, releasing the PD-1 pathway-mediated inhibition of the immune
- LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC High-Risk CSCC
Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
|
|
英文每年常用名排名
2024 年排名
2023 年排名
2022 年排名
2021 年排名
2020 年排名
2019 年排名
2018 年排名
2017 年排名
2016 年排名
2015 年排名
2014 年排名
2013 年排名
2012 年排名
2011 年排名
2010 年排名
2009 年排名
2008 年排名
2007 年排名
2006 年排名
2005 年排名
2004 年排名
2003 年排名
2002 年排名
2001 年排名
英文名字起源
希伯来
希腊
条顿
印度
拉丁
拉丁语
古英语
英格兰
阿拉伯
法国
盖尔
英语
匈牙利
凯尔特
西班牙
居尔特
非洲
美洲土著
挪威
德国
威尔士
斯拉夫民族
古德语
爱尔兰
波斯
古法语
盎格鲁撒克逊
意大利
盖尔语
未知
夏威夷
中古英语
梵语
苏格兰
俄罗斯
土耳其
捷克
希腊;拉丁
斯干那维亚
瑞典
波兰
乌干达
拉丁;条顿
巴斯克语
亚拉姆
亚美尼亚
斯拉夫语
斯堪地纳维亚
越南
荷兰
|